These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
358 related items for PubMed ID: 35032765
1. How I treat biliary tract cancer. Lamarca A, Edeline J, Goyal L. ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765 [Abstract] [Full Text] [Related]
2. Systemic treatment of advanced or recurrent biliary tract cancer. Zhang W, Zhou H, Wang Y, Zhang Z, Cao G, Song T, Zhang T, Li Q. Biosci Trends; 2020 Nov 04; 14(5):328-341. PubMed ID: 32830166 [Abstract] [Full Text] [Related]
3. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. Merters J, Lamarca A. J Hepatol; 2023 Mar 04; 78(3):652-657. PubMed ID: 36400328 [Abstract] [Full Text] [Related]
9. Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma. Wheless M, Agarwal R, Goff L, Lockney N, Padmanabhan C, Heumann T. Curr Treat Options Oncol; 2024 Jan 04; 25(1):127-160. PubMed ID: 38177560 [Abstract] [Full Text] [Related]
15. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M. Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314 [Abstract] [Full Text] [Related]
16. Will advanced cholangiocarcinoma become a targetable malignancy? Sarkis Y, Al Soueidy A, Kourie HR. Crit Rev Oncol Hematol; 2021 Mar 15; 159():103233. PubMed ID: 33482346 [Abstract] [Full Text] [Related]
17. [Not Available]. Valéry M, Cervantes B, Smolenschi C, Boige V, Ducreux M, Cohen R, Hollebecque A. Bull Cancer; 2022 Nov 15; 109(11S):11S21-11S27. PubMed ID: 36535759 [Abstract] [Full Text] [Related]
18. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, Warth A, Vogel MN, Mehrabi A, Hafezi M, Boehmer K, von Deimling A, Schirmacher P, Weichert W, Capper D. Mod Pathol; 2014 Jul 15; 27(7):1028-34. PubMed ID: 24309328 [Abstract] [Full Text] [Related]
19. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. Lamarca A, Barriuso J, McNamara MG, Valle JW. J Hepatol; 2020 Jul 15; 73(1):170-185. PubMed ID: 32171892 [Abstract] [Full Text] [Related]
20. Current options and future directions of systemic therapy for advanced biliary tract cancer. Prete MG, Cammarota A, D'Alessio A, Zanuso V, Rimassa L. Explor Target Antitumor Ther; 2021 Jul 15; 2(5):416-433. PubMed ID: 36045701 [Abstract] [Full Text] [Related] Page: [Next] [New Search]